Mounjaro®
Starting from £179.99/mo
Start journey Learn moreConstipation is one of the most commonly reported side effects of semaglutide treatment. Clinical trial data from the STEP programme, reviewed by the NHS, found that bowel changes affected a meaningful proportion of participants — and for some, constipation was the issue rather than the more-discussed nausea. It is a prescription-only medicine, and a prescriber will weigh this alongside your full health picture before treatment begins. Understanding why it happens and what genuinely helps makes a real difference to how you get through the early weeks.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity over 68 weeks and captured gastrointestinal events systematically. Constipation was among the most frequently reported GI side effects in the semaglutide group, alongside nausea and diarrhoea. This was not a surprise finding: Wegovy works partly by slowing the rate at which food leaves your stomach, a mechanism called delayed gastric emptying. When transit slows in the stomach, the same effect can ripple further down the gut, reducing the frequency and ease of bowel movements.
The NHS medicines page for semaglutide lists constipation as a common side effect, meaning it affects between one in ten and one in a hundred people. That bracket is wide because individual responses vary considerably. Some people notice nothing beyond mild changes; others find the first few weeks genuinely uncomfortable. What the data consistently show is that GI symptoms are generally at their peak when a dose is first introduced or increased, then ease as the body adapts.
If you are reading about this before starting treatment, that pattern matters. The discomfort you experience in week one or two at a new dose is rarely the same as week six. And if you are wondering whether Wegovy is the direct cause of what you are experiencing, the short answer is: yes, for many people it is, and yes, it is manageable. Our guide to Wegovy and constipation explains in detail why the medicine affects the bowel and what that typically looks like in practice.
There is no single fix, but several approaches consistently appear in NHS advice on managing constipation while on GLP-1 medicines. Fluid intake is the first and most underestimated lever. When gastric emptying slows, dehydration risk rises, especially if you are also eating less and therefore taking in less water from food. Aim for regular, steady fluid intake throughout the day, not a large amount at once.
Dietary fibre matters too, though the type makes a difference. Soluble fibre, found in oats, lentils, cooked vegetables and fruit, tends to be better tolerated on semaglutide than insoluble fibre (such as raw bran or high-fibre breakfast cereals), which can worsen bloating. Eating slowly and in smaller portions also reduces the overall load on a gut that is already moving more slowly.
Physical movement, even gentle walking, supports gut motility in ways that sitting still does not. If you want specific, step-by-step advice on how to stop constipation on Wegovy, our dedicated guide walks through each practical measure in order. For a more detailed look at specific relief strategies, including when to consider an over-the-counter remedy, our dedicated guide covers each option clearly.
If symptoms are persistent rather than intermittent, speak to your prescriber before reaching for stimulant laxatives. Osmotic laxatives such as macrogol (Movicol) are generally considered more appropriate first-line options alongside a GLP-1 medicine, but this is a clinical conversation, not a self-management decision. If you are already experiencing symptoms and want to understand how to help constipation on Wegovy, our guide covers both immediate comfort measures and longer-term adjustments you can discuss with your prescriber.
Most constipation on Wegovy is inconvenient rather than dangerous. But there are symptoms that change the picture entirely, and it is worth knowing them clearly before they arise.
Severe abdominal pain that does not resolve within a few hours, particularly pain that spreads toward your back or is accompanied by vomiting, is not ordinary constipation. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 receptor agonist medicines. The symptom profile can overlap with gut discomfort, which is exactly why the MHRA's guidance is clear: persistent, severe stomach pain warrants same-day medical assessment, not watchful waiting.
Other signs that need prompt attention include blood in your stool, complete absence of bowel movements for more than four or five days, vomiting that prevents you from keeping fluids down, or signs of dehydration such as dizziness and dark urine. These symptoms go beyond the expected GI adjustment period and should be assessed by a GP or, if severe, in an emergency setting.
If you are unsure whether what you are experiencing is within the normal range, our aftercare team is available seven days a week. You can also report any suspected side effect directly to the MHRA through the Yellow Card scheme at yellowcard.mhra.gov.uk, this applies whether or not you think the symptom is serious.
Side effects like constipation are part of the full picture our prescribers consider before recommending treatment. The consultation is not a checklist; it is a genuine clinical review of your health, your history and what to expect. If you have had significant bowel problems in the past, or if constipation feels like a barrier to starting, that is exactly the kind of thing to raise.
Every repeat order at nume is reviewed clinically before it is dispensed. If something changes between orders (including a side effect you did not expect) that review is the moment to flag it. You can read more about what our team considers and who oversees it on the clinical team page. If you are still weighing up whether treatment is right for you, the Wegovy overview covers the full picture, or you can start a free consultation and let our prescribers discuss suitability with you directly.
Treatment arrives tracked by DPD the next working day, in plain unbranded packaging, no indication of what is inside. What matters more than the packaging is having someone qualified in your corner when questions come up. That is what the consultation, and the aftercare that follows, are for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.